Clareo Health | A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Disease Related
* Histologically or cytologically confirmed non-small cell lung cancer.
* Subjects must have advanced non-small cell lung cancer defined as stage IIIB with malignant pleural effusion or stage IV or recurrent disease.
* Planning to receive up to 6 cycles of chemotherapy
* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 Demographic
* Men or women \> 18 years of age Ethical
* Adequate Hematological, renal, hepatic and coagulation function General
* Plan to begin protocol specific therapy \< 7 days after enrollment/randomization
* Prior chemotherapy as follows:
* Any prior chemotherapy for advanced non-small cell lung cancer
* Any prior adjuvant chemotherapy for non-small cell lung cancer \< 52 weeks prior to enrollment/randomization. Adjuvant chemotherapy completed \> 52 weeks prior to randomization is permitted.
* Any prior chemoradiation.
* Central (chest) radiation therapy \< 28 days prior to randomization, radiation therapy for peripheral lesions \< 14 days prior to enrollment/randomization
* Other abnormal medical conditions
* Documented myocardial infarction or unstable/uncontrolled cardiac condition
* History of arterial thrombosis, pulmonary embolus, deep vein thrombosis or hemorrhagic disorders
* Major surgical procedure \< 30 days prior to enrollment/randomization or not yet recovered from prior major surgery, Minor surgical procedure \< 7 days prior to enrollment/randomization or not yet recovered from prior minor surgery
